A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With Metformin in Subjects With Type 2 Diabetes.
Phase of Trial: Phase III
Latest Information Update: 03 Jun 2015
At a glance
- Drugs Alogliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 10 Jun 2017 Biomarkers information updated
- 07 Jul 2009 Actual initiation date changed from Feb 2006 to Mar 2006 as reported by ClinicalTrials.gov.
- 07 Jul 2009 Actual end date changed from Jan 2007 to Jun 2007 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History